[go: up one dir, main page]

PE20061107A1 - Composiciones de tigeciclina y metodos para su preparacion - Google Patents

Composiciones de tigeciclina y metodos para su preparacion

Info

Publication number
PE20061107A1
PE20061107A1 PE2006000281A PE2006000281A PE20061107A1 PE 20061107 A1 PE20061107 A1 PE 20061107A1 PE 2006000281 A PE2006000281 A PE 2006000281A PE 2006000281 A PE2006000281 A PE 2006000281A PE 20061107 A1 PE20061107 A1 PE 20061107A1
Authority
PE
Peru
Prior art keywords
acid
preparation
refers
methods
composition
Prior art date
Application number
PE2006000281A
Other languages
English (en)
Inventor
Mahdi B Fawzi
Tianmin Zhu
Syed M Shah
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36648809&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20061107(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20061107A1 publication Critical patent/PE20061107A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A)TIGECICLINA; B) UN CARBOHIDRATO APROPIADO SELECCIONADO ENTRE LACTOSA, MANOSA, SUCROSA Y GLUCOSA; C) UN ACIDO REGULADOR TAL COMO HCl 1.0, ACIDO GENTISICO. LA COMPOSICION ES LIOFILIZADA Y TIENE UN pH ENTRE 3,0 Y 7,0. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION. DICHA COMPOSICION PROPORCIONA MAYOR ESTABILIDAD CONTRA LA FORMACION DEL EPIMERO A pH ACIDOS ADEMAS DE MINIMIZAR LA DEGRADACION OXIDATIVA UTILES EN EL TRATAMIENTO CONTRA BACTERIAS RESISTENTES A FARMACOS TALES COMO ESTAFILOCOCOS, ENTEROCOCCI, ESTERPTOCOCOS PNEUMONIAE, ENTRE OTROS
PE2006000281A 2005-03-14 2006-03-13 Composiciones de tigeciclina y metodos para su preparacion PE20061107A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66103005P 2005-03-14 2005-03-14

Publications (1)

Publication Number Publication Date
PE20061107A1 true PE20061107A1 (es) 2006-12-08

Family

ID=36648809

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000281A PE20061107A1 (es) 2005-03-14 2006-03-13 Composiciones de tigeciclina y metodos para su preparacion

Country Status (25)

Country Link
US (5) US7879828B2 (es)
EP (1) EP1858488B2 (es)
JP (1) JP4972081B2 (es)
KR (2) KR101354093B1 (es)
CN (2) CN101132775A (es)
AR (2) AR053827A1 (es)
AU (1) AU2006223226B2 (es)
BR (1) BRPI0608464A2 (es)
CA (1) CA2602089C (es)
CR (1) CR9416A (es)
CY (1) CY1114504T1 (es)
DK (1) DK1858488T4 (es)
ES (1) ES2434944T5 (es)
GT (1) GT200600112A (es)
HN (1) HN2006011218A (es)
IL (1) IL185924A (es)
MX (1) MX2007010983A (es)
NO (1) NO20074278L (es)
PE (1) PE20061107A1 (es)
PL (1) PL1858488T5 (es)
PT (1) PT1858488E (es)
RU (1) RU2428190C2 (es)
TW (1) TW200700092A (es)
WO (1) WO2006099258A1 (es)
ZA (1) ZA200707831B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200700092A (en) 2005-03-14 2007-01-01 Wyeth Corp Tigecycline compositions and methods of preparation
AR057649A1 (es) * 2005-05-27 2007-12-12 Wyeth Corp Formas solidas cristalinas de tigeciclina y metodos para preparar las mismas
AR055336A1 (es) * 2005-06-16 2007-08-22 Wyeth Corp Proeso de elaboracion para la produccion de tigeciclina como un polvo reconstituible, polvo de tigeciclina liofilizado y producto hecho mediante el proceso
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US20070244335A1 (en) * 2006-04-17 2007-10-18 Teva Pharmaceutical Industries Ltd. Isolation of tetracycline derivatives
US8198470B2 (en) * 2006-04-24 2012-06-12 Teva Pharmaceutical Industries Ltd. Crystalline form II of tigecycline and processes for preparation thereof
ES2622356T3 (es) * 2006-04-24 2017-07-06 Teva Pharmaceutical Industries, Ltd. Formas cristalinas de tigeciclina y procesos para su preparación
FR2910812B1 (fr) * 2006-12-29 2009-03-20 Pierre Fabre Medicament Sa Compositions pharmaceutiques injectables lyophilisees de derives hemi-synthetiques d'alcaloide de vinca stables a temperature ambiante
PT2271348T (pt) * 2008-03-28 2018-04-16 Paratek Pharm Innc Formulação de comprimido oral de composto de tetraciclina
US9107929B2 (en) 2008-05-01 2015-08-18 Ranbaxy Laboratories Limited Stable parenteral formulations of tigecycline
US20100035845A1 (en) * 2008-08-06 2010-02-11 Wyeth Tigecycline formulations
CN102138925B (zh) * 2010-01-29 2014-06-25 正大天晴药业集团股份有限公司 替加环素组合物及其制备方法
JP6025712B2 (ja) * 2010-05-12 2016-11-16 レンペックス・ファーマシューティカルズ・インコーポレイテッド テトラサイクリン組成物
JPWO2012169435A1 (ja) 2011-06-07 2015-02-23 旭化成ファーマ株式会社 高純度ｐｔｈ含有凍結乾燥製剤およびその製造方法
CN102391148B (zh) * 2011-10-24 2014-01-08 江苏奥赛康药业股份有限公司 一种高纯度替加环素的合成方法
CN103315947B (zh) 2012-03-22 2016-01-20 上海汇伦生命科技有限公司 一种注射用替加环素组合物
CN103356662B (zh) * 2012-03-27 2015-11-25 浙江医药股份有限公司新昌制药厂 注射用替加环素组合物及其制备方法
CN102641249A (zh) * 2012-05-06 2012-08-22 江苏奥赛康药业股份有限公司 一种替加环素组合物的制备方法
CN103417498B (zh) * 2012-05-18 2017-09-12 山东新时代药业有限公司 一种替加环素冻干粉针剂的制备方法
CN102697739B (zh) * 2012-05-31 2014-10-29 丽珠医药集团股份有限公司 一种减少替加环素差向异构体化的粉针剂制备方法
CN102911077B (zh) * 2012-11-12 2015-01-07 成都百裕科技制药有限公司 4r-替加环素的制备方法
WO2014167575A2 (en) 2013-03-26 2014-10-16 Astron Research Limited Stable tigecycline composition
IN2013MU01127A (es) 2013-03-26 2015-05-01 Astron Res Ltd
CN104107170A (zh) * 2013-04-22 2014-10-22 上海汇伦生命科技有限公司 一种替加环素组合物
US20140323443A1 (en) * 2013-04-30 2014-10-30 Fresenius Kabi Usa, Llc Tigecycline formulations
US20160143925A1 (en) 2013-11-12 2016-05-26 Galenicum Health S.L. Stable pharmaceutical compositions
NO2723977T3 (es) 2014-03-19 2018-03-10
CN105079816B (zh) * 2015-08-17 2018-09-07 江苏豪森药业集团有限公司 替加环素药物组合物及其制备方法
CN108653216B (zh) * 2018-05-28 2020-12-18 福安药业集团湖北人民制药有限公司 注射用替加环素
WO2021063468A1 (en) 2019-10-02 2021-04-08 Anfarm Hellas S.A. Stable parenteral pharmaceutical composition containing tigecycline and process for the preparation thereof
CN113582870A (zh) * 2020-05-01 2021-11-02 复旦大学附属华山医院 一种恢复替加环素抗菌活性的方法
IT202100031133A1 (it) 2021-12-13 2023-06-13 Zambon Spa Composizione farmaceutica comprendente tigeciclina

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH225704A (de) 1942-01-06 1943-02-15 Schlotterbeck Automobile Aktie Holzgasgenerator.
GB901107A (en) 1959-06-29 1962-07-11 Pfizer Therapeutic composition and method of preparing same
US3026248A (en) 1959-09-11 1962-03-20 Pfizer & Co C Thioglycerol and formaldehyde sulfoxylate stabilized tetracycline antibiotics in polyhydric alcohol solvents
US3106512A (en) 1961-07-19 1963-10-08 Olin Mathieson Stabilization of tetracycline base in dry form with glucono delta lactone
US3145228A (en) 1962-09-06 1964-08-18 Pfizer & Co C 5-alkoxy-and 5-benzyloxy-tetracycline, derivatives and analogues thereof
US3219529A (en) 1962-10-04 1965-11-23 American Cyanamid Co Stable tetracycline solutions
US4038315A (en) 1972-05-11 1977-07-26 American Cyanamid Company Isolation and recovery of calcium chloride complex of 7-dimethylamino-6-dimethyl l-6-deoxytetracycline hydrochloride
DE2748132A1 (de) 1977-10-27 1979-05-03 Behringwerke Ag Stabilisator fuer polysaccharid
US4457916A (en) 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
US4678812A (en) 1986-05-30 1987-07-07 E. I. Du Pont De Nemours And Company Trehalose as stabilizer and tableting excipient
US5122519A (en) 1989-06-27 1992-06-16 American Cyanamid Company Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
ATE215247T1 (de) 1990-06-22 2002-04-15 Canon Kk Bildverarbeitungsvorrichtung
US5494903A (en) 1991-10-04 1996-02-27 American Cyanamid Company 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
US5538954A (en) 1994-06-24 1996-07-23 A/S Dumex (Dumex Ltd.) Salts of tetracyclines
US5675030A (en) * 1994-11-16 1997-10-07 American Cyanamid Company Method for selective extracting a 7-(hydrogen or substituted amino)-9- (substituted glycyl) amido!-6-demethyl-6-deoxytetracycline compound
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US5908838A (en) 1998-02-19 1999-06-01 Medics Pharmaceutical Corporation Method for the treatment of acne
JP2003509367A (ja) 1999-09-14 2003-03-11 オラファーマ， インコーポレイテッド 粘膜炎を治療または予防するための処方物
WO2002012170A1 (en) 2000-08-04 2002-02-14 Trustees Of Tufts College 8-substituted tetracycline compounds
WO2002055731A2 (en) 2001-01-11 2002-07-18 Board Of Regents, The University Of Texas System Dosage adjustement for antibiotics
WO2002096354A2 (en) 2001-05-29 2002-12-05 Tap Pharmaceutical Products Inc. Enhancement of oral bioavailability of non-emulsified formulation of prodrug esters with lecithin
EP2301915A1 (en) 2001-07-13 2011-03-30 Paratek Pharmaceuticals, Inc. 7-(diethylamino)methyl substituted tetracycline having target therapeutic activities
US20030171340A1 (en) 2002-02-07 2003-09-11 Jenefir Isbister Methods of disease treatment using metal-complexed tetracycline antibiotics
CN1390550A (zh) 2002-07-25 2003-01-15 于航 盐酸米诺环素冻干粉针剂及其制备方法
WO2004038000A2 (en) 2002-10-24 2004-05-06 Paratek Pharmaceuticals, Inc. Methods of using substituted tetracycline compounds to modulate rna
WO2004078111A2 (en) 2003-03-06 2004-09-16 Ranbaxy Laboratories Limited Extended release minocycline compositions and processes for their preparation
CN1568999A (zh) † 2003-07-14 2005-01-26 南宁枫叶药业有限公司 稳定的医药用河豚毒素冷冻干燥制剂
US20050148553A1 (en) 2003-09-05 2005-07-07 Testa Raymond T. Use of tigecycline, alone, or in combination with rifampin to treat osteomyelitis and/or septic arthritis
GB2414668B (en) 2004-06-03 2009-07-29 Dexcel Ltd Tetracycline modified release delivery system
KR20070069182A (ko) 2004-10-28 2007-07-02 와이어쓰 티게시클린 및 디곡신의 공동투여
TW200700092A (en) 2005-03-14 2007-01-01 Wyeth Corp Tigecycline compositions and methods of preparation
AR057034A1 (es) 2005-05-27 2007-11-14 Wyeth Corp Metodos para purificar tigeciclina
WO2014191552A1 (en) † 2013-05-31 2014-12-04 Xellia Pharmaceuticals Aps A method for stabilizing tigecycline

Also Published As

Publication number Publication date
CR9416A (es) 2008-03-06
WO2006099258A1 (en) 2006-09-21
PL1858488T5 (pl) 2024-01-03
JP4972081B2 (ja) 2012-07-11
KR20130122988A (ko) 2013-11-11
US20160144036A1 (en) 2016-05-26
US10588975B2 (en) 2020-03-17
DK1858488T3 (da) 2013-11-04
US7879828B2 (en) 2011-02-01
US20060247181A1 (en) 2006-11-02
ZA200707831B (en) 2011-02-23
DK1858488T4 (da) 2022-09-12
PT1858488E (pt) 2013-11-18
WO2006099258A8 (en) 2007-10-04
MX2007010983A (es) 2007-09-19
CN101132775A (zh) 2008-02-27
EP1858488A1 (en) 2007-11-28
PL1858488T3 (pl) 2014-01-31
EP1858488B1 (en) 2013-09-11
AR053827A1 (es) 2007-05-23
AU2006223226B2 (en) 2012-03-15
CA2602089A1 (en) 2006-09-21
CN102512429A (zh) 2012-06-27
EP1858488B2 (en) 2022-07-20
RU2007131396A (ru) 2009-04-20
HN2006011218A (es) 2008-09-17
US20170266290A1 (en) 2017-09-21
GT200600112A (es) 2006-11-29
NO20074278L (no) 2007-11-20
CA2602089C (en) 2013-04-30
CY1114504T1 (el) 2016-10-05
RU2428190C2 (ru) 2011-09-10
KR20080002828A (ko) 2008-01-04
US8975242B2 (en) 2015-03-10
KR101354093B1 (ko) 2014-01-24
IL185924A0 (en) 2008-01-06
US20150141379A1 (en) 2015-05-21
ES2434944T3 (es) 2013-12-18
AR109500A2 (es) 2018-12-19
BRPI0608464A2 (pt) 2010-01-05
US20110118216A1 (en) 2011-05-19
JP2008533146A (ja) 2008-08-21
TW200700092A (en) 2007-01-01
ES2434944T5 (es) 2022-10-20
US9254328B2 (en) 2016-02-09
IL185924A (en) 2014-05-28
US9694078B2 (en) 2017-07-04
AU2006223226A1 (en) 2006-09-21

Similar Documents

Publication Publication Date Title
PE20061107A1 (es) Composiciones de tigeciclina y metodos para su preparacion
BRPI0518101A (pt) métodos de produção e sìntese de composições nanoparticuladas, composições obtidas e seu uso
BR112012006283A2 (pt) formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte
CL2020000468A1 (es) Uso de una formulación estable que comprende una enzima de reemplazo para la enzima lisosomal (divisional solicitud 201801220)
GB2480773A (en) Compositions and methods for the treatment or the preventation oral infections by E.Coli
CL2015002412A1 (es) Composición farmacéutica sólida de daptomicina; método de fabricación; y uso para tratar infecciones bacterianas (divisional de la sol. 1336-2012)
AR056055A1 (es) Complejos cristalinos e hidratos de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-etinil-bencil)-benceno
UY29410A1 (es) Composiciones farmacéuticas en base a metilamidas del ácido 4-(4-/-3(-4-cloro-3-trifluorometifenil)ureido)fenoxi)piridin-2-carboxílico, procedimiento de preparación y aplicaciones.
NO20075136L (no) Nye liposompreparater
NZ595382A (en) Combination therapy involving n-(5-(tert-butyl-isoxazol-3-yl)-n’-{ 4-(7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl} urea
BR112014008700A2 (pt) composições úteis no tratamento de nefropatia e processos para preparação das mesmas
TW200637614A (en) Bendamustine pharmaceutical compositions
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
AR058679A1 (es) Preparacion farmaceutica que contiene meloxicam
BRPI0612672B8 (pt) composição de extrato aquoso de alga verde-azulada
NZ594019A (en) Novel antibacterial agents for the treatment of gram positive infections
BRPI0606132A2 (pt) formas cristalinas de docetaxel e processos para seu preparo
BR112012022209A2 (pt) composições farmacêuticas compreendendo monoterpenos
GB2456475A (en) Composition for the treatment of skin conditions
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
NZ598702A (en) A micro-rna family that modulates fibrosis and uses thereof
IL186058A0 (en) Polymorphs of 3-0-(3',3' -dimethylsuccinyl) betulinic acid di-n-methyl-d-glucamine salt
BRPI0712312A2 (pt) Composto, processo para a produção do mesmo, composição farmacêutica, agente antimicrobiano, agente anti-mrsa, método para a prevenção ou o tratamento de uma doença infecciosa, e, uso do composto
BR0111683A (pt) Remédios para doenças alérgicas e processo de produção do mesmo
PE20130308A1 (es) Metodos para tratar infecciones bacterianas recurrentes

Legal Events

Date Code Title Description
FX Voluntary withdrawal